NANO Fundamentale Forhold (NANOV)

[Tony1]

I doubt that this is production for NANOV! there are a lot of other clients.

[hybrid]

Det utsagnet der slår en skeiv spiker rett.

Kunne ikke vært mer enig.

[anon57124368]

Jepp, akk akk

[kanon]

@vegar_beider

Without replacing this aging infrastructure, the EU could experience significant radioisotope shortages and impede
access to vital treatments for its citizens. These shortages may impact the roll-out of lutetium-177 (177Lu) based

Såeeehh altså, har ikke nano et fiks ferdig bemannet moderne produksjonsoppsett som går på tomgang for 50-70 mill per måned?

Lei ut til disse for 100 mill + per mnd.

Å fyyf​:rocket:

[TheObserver]

De er vel de som har fått en earn-out på 50 MNOK i løpet av Q4 2021 og Q1 2022?

[kanon]

Nei, de utbetalingene mener jeg var milepæls utbetalinger til CRO.

Men fra spøk til revolver, nano sin cmc alene burde være verdt endel kroner for BP om de sliter med slikt.

[TheObserver]

Det blir i alle fall et relevant tema snarlig, regner med at @Pk2k allerede har slengt avgårde en mail til Skullerud for å høre om Novartis er de eneste som sliter her.

Som kjent er jo disse to i nært samarbeid med hverandre allerede, og kanskje NANOV har en leverage overfor Novartis på tilgjengelig produksjon. Jeg er villig til å la aksjene mine gå for 120 NOK, det burde være småtteri for Novartis for å sikre egen produksjon og en state of the art pipe

[TyrionIV]

Skullerud snakket jo noe om å effektivisere cmc eller noe slikt på q-callen - kan jo være de ser litt forbedrings/innsparingspotensiale der(?)

[TekBot]

Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

Oslo, Norway, 20 May 2022

Reference is made to the minutes from Nordic Nanovector ASA’s (the “Company”)
…

Vis børsmeldingen

(OSE: NANOV) annual general meeting held on 28 April 2022 in Oslo, Norway (the
“AGM”).

At the AGM, the shareholders approved the issuance of restricted stock units
(“RSUs”) to board members who elect to receive all or parts of their
remuneration, for the period from the annual general meeting in 2022 to the
annual general meeting in 2023, in the form of RSUs.

The RSUs are non-transferable and each RSU give the right and obligation to
acquire one share in the Company at a price of NOK 0.20 per share (corresponding
to the nominal value of the shares) subject to satisfaction of the applicable
vesting conditions stated in the RSU agreements.

The board members may elect to either (i) receive 100% of the compensation in
RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii)
receive 2/3 of the compensation in cash and 1/3 in RSUs. The election made by
each board member has been set out in the table below. The number of RSUs to be
granted to the members of the Board of Directors is calculated as the NOK amount
of the RSU opted portion of total minimum compensation to the board member,
divided by the market price for the Nordic Nanovector share. The market price is
calculated as volume weighted average share price 10 trading days prior to the
date of the AGM, i.e. NOK 14.28.

Pursuant to the RSU program, the board members have made the following election
and hold the following number of RSUs and shares following such election:

[][][][][][]
Name Remuneration Allocation Number of Total number of Total
for between RSUs for RSUs out number of
the period cash and the -standing shares
2022 RSUs period
-23 2022-23
Jan H. NOK 1/3 RSUs 14,939 39,593 32,617
Egberts 640,000
[1]
Solveig NOK 100% RSUs 25,910 39,539 1,786
Hellebust 370,000
[2]
Karin NOK 1/3 RSUs 8,636 18,817 1,286
Meyer 370,000
[3]
Joanna NOK 390,000 1/3 RSUs 9,103 13,905 25,240
Horobin [4]
Jean NOK 370,000 1/3 RSUs 8,636 13,438 20,452
-Pierre [5]
Bizzari
Thomas NOK 1/3 RSUs 8,169 8,169 8,500
Ramdahl 350,000
[6]

1. NOK 600,000 as chairman of the Board, NOK 20,000 as a member of the audit
   committee and NOK 20,000 as member of the compensation committee.

2. NOK 330,000 as board member and NOK 40,000 as chair of the compensation
   committee.

3. NOK 330,000 as board member and NOK 40,000 as chair of the audit committee.

4. NOK 330,000 as board member, NOK 20,000 as member of the audit committee, NOK
   20,000 as member of the compensation committee and NOK 20,000 as member of the
   clinical committee.

5. NOK 330,000 as board member and NOK 40,000 as chair of the clinical
   committee.

6. NOK 330 000 as board member and NOK 20,000 as member of the clinical
   committee.

A total of 75,393 RSUs have thus been allocated following the AGM. The RSUs will
vest on 28 April 2023. For further information about the RSU Program see section
6.3.2 to the Company’s financial statements for 2021, included in the Company’s
annual report for 2021 on page 89.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com (http://about/)

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs. The Company aspires to become a
leader in the development of CD37-targeted therapies for haematological cancers
and immune diseases. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 27 billion by 2029. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Kilde

[Stranger_DK]

Fortjener de det?

[diffish]

Selvfølgelig skal styret få lønn for jobben de gjør. Og det er hyggelig at de vil ha det i RSUer og ikke bare cash.

[polygon]

Eh, alle bortsett fra en valgte vel så mye cash og så lite RSU som de kunne?

[diffish]

Godt poeng. Men likevel. Selvfølgelig skal styret få betalt for jobben sin. De som har valgt mye RSUer tidligere har vel ikke akkurat hatt så mye å juble over

[TyrionIV]

@TekBot

The market price is calculated as volume weighted average share price 10 trading days prior to the
date of the AGM, i.e. NOK 14.28.

Hmm… Hadde vel vært et bedre signal om alle gjorde som Hellebust, men kanskje ikke så overraskende at man velger cash over RSU når RSU verdsettes 25 % høyere enn aksjekursen.

[TekBot]

Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment

Oslo, Norway, 2 June 2022

Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its
…

Vis børsmeldingen

ongoing Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]
-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).

As highlighted at the recent Q1 results, reported on 13 May 2022, recruitment
into PARADIGME has been slower than anticipated, and despite ongoing efforts by
the company this has continued into Q2 with no additional patients enrolled in
May.

As a result, the Board of Nordic Nanovector has decided to conduct a
comprehensive review of all aspects of the PARADIGME study. In order to fully
protect the integrity of the study an independent evaluation of the data
collected to date has been commissioned and will be analysed by an Independent
Expect Panel. This information will then be used to determine the best path
forward for the study. PARADIGME will continue to enrol patients while the
independent evaluation is ongoing.

The current guidance for delivery of initial top line data from PARADIGME in the
second half of this year will be reviewed concurrently.

The Board expects to report on the findings of the review of PARADIGME no later
than the Q2 results to be released on 20 July 2022 and will not be commenting
further until the review is complete.

The Board believes that this review of PARADIGME is in the best interests of all
shareholders and the patients who Nordic Nanovector is targeting in this study
to determine the optimal path forward for Betalutin[®] within a timeframe that
is financially and commercially viable.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to
Betalutin[®] and intends to actively participate in the commercialisation of
Betalutin[®] in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Norwegian Securities Trading Act.

Kilde

[TekBot]

Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

Oslo, Norway, 10 June 2022

Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05
…

Vis børsmeldingen

Phase 1 trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in
patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not
eligible for stem cell transplantation.

The latest data to be presented at the European Hematology Association (EHA)
Congress in Vienna, Austria on 10 June 2022 shows that Betalutin® continues to
be well tolerated with no further dose-limiting toxicity (DLT). The data
analysis showed that clinical activity of Betalutin® was seen with two complete
responses out of 16 evaluable patients.

Erik Skullerud, Nordic Nanovector CEO, commented: “This update from the LYMRIT
37-05 trial being presented at EHA shows two complete responses, demonstrating
early signs of efficacy for Betalutin® in this fragile and heavily pre-treated
patient population. Importantly this is combined with a consistently good safety
profile. There remains a need for combination therapies that provide high
response rates with a curative intent and a low side effect burden for R/R DLBCL
patients, and we continue to explore the options for advancing Betalutin® in
this setting with the right therapeutic combination partner.”

Details of the poster presentation on 10 June at EHA are as follows:

Title: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL
LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

Authors: Illidge T, Beasley M, Gomez Codina J, Vavallo F, Pascal V, Wills V

Session Title: Poster session

Session date and time: Friday, June 10 202 - 16:30 - 17:45 CEST

Final Abstract Code: P1165

About LYMRIT 37-05

The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation
study designed to assess the safety and preliminary anti-tumour activity of a
single administration of Betalutin®. Patients were enrolled at clinical trial
sites in the US and Europe. More information on this study can be found at
www.clinicaltrials.gov (NCT02658968).

The starting doses of Betalutin® and lilotomab were 10 MBq/kg and 60 mg (Cohort
1, n=3), respectively, and then Betalutin® 10 MBq/kg and lilotomab 100 mg
(Cohort 2, n=3 treated with Betalutin®). Cohort 3 received 15 MBq/kg and
lilotomab 100 mg (n=3) and Cohort 4 received 20 MBq/kg and lilotomab 100 mg
(n=7).

About DLBCL

DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for up
to 43% of all NHL cases, making it the most common form of the disease.
Approximately 40% of DLBCL patients relapse after first-line combination
treatment with rituximab and chemotherapy and only 30-40% of relapsed patients
respond with subsequent high-dose chemotherapy followed by Stem Cell
Transplantation (ref. 1). There are currently very few therapeutic options for
patients not eligible for SCT, which makes relapsed DLBCL a serious unmet
medical need. The number of diagnosed incident cases of DLBCL in the 7 major
markets (U.S., and key 5 European markets and Japan) was 64,172 in 2018 and is
expected to be 74,927 in 2028 (ref. 2). The value of the 3L DLBCL market
segment in the key 7 pharma markets is expected to increase from USD 0.6B in
2019 to USD 1.3B in 2028, the value of the 2L DLBCL market segment is expected
to increase from USD 0.4B in 2019 to USD 2.0B in 2028. (ref. 2).

1. L.S. Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse
   large B cell lymphoma (2014) South Asian J. Cancer 3(1): 66-70

2. NHL and CLL Report, CRG, 2000, Disease Landscape and Forecast

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.

Kilde

[TekBot]

Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma

Oslo, Norway, 21 June 2022

Nordic Nanovector ASA (OSE: NANOV) today provides an update following its
…

Vis børsmeldingen

comprehensive review and independent data evaluation of PARADIGME, its ongoing
Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line
relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).

The independent expert panel reviewed the efficacy data collected to date.
Betalutin®, at the selected dose of 15 MBq/kg after a pre-dose of 40 mg
lilotomab (40/15), has continued to display an attractive safety profile. While
Betalutin® showed signs of efficacy in this frail, elderly and difficult-to
-treat patient population, the independent expert panel reported that the
efficacy data are less promising than the data reported from the Phase 2a LYMRIT
37-01 trial. The Company intends to seek further guidance from the competent
regulatory authorities, including the US Food and Drug Administration (FDA),
regarding the way forward for PARADIGME. Pending regulatory feedback, the study
will remain open for recruitment.

Following interaction with the regulatory authorities, the Company will provide
an additional update, which is expected in August. The Company will not be
commenting further until then. The Company’s Q2 results will be rescheduled to
August and a new date will be confirmed in due course.

Given the continuing slow patient recruitment, Nordic Nanovector does now not
expect to deliver preliminary top line data from PARADIGME in H2 2022.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to
Betalutin[®] and intends to actively participate in the commercialisation of
Betalutin[®] in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Norwegian Securities Trading Act.

Kilde

[ath100]

Føler for å forlate panikken på småprat i håp om litt faglighet på fundamentaltråden.

Hva har skjedd med data? Det ligger jo alt et nokså stort materiale fra Lymrit og Paradigme fram til interim. Satt langt ut på spissen, så vil statistikken totalt sett være “brukbar” selv med null effekt på de som er innrullert etter interim.

Når de erstatter “encouraging” med “shows signs of activity” så høres det dramatisk ut, og ikke som et godt utgangspunkt for godkjenning.

Noen som har noen tanker?
-Hva er nivået på resultatene
-Hva er årsaken?

[Hallakis]

Altså, om man antar - basert på uttalelsene om at interim var «ekstremt oppmuntrende» - at interim lå på høyde med Lymrit. Og Lymrit var 60%ORR/30%CR etter husken?

Om man videre antar at interim ble kjørt på 50 pax og at ingen av de resterende 58 pax har noe effekt, vil worst case være ORR 27%|CR 13%. Om jeg regner rett vel og merke?

[ath100]

Ja det var den typen argumentasjon jeg var på jakt etter.

Man kan spekulere i om det har svekket Paradigme å endre inklusjonskriteriene, eller om det bare er de store talls lov som slår inn. Eller om det var feil å velge 15/40. Eller om tallene bare er dårligere, uten å være dårlige.

Personlig likte jeg dårlig vendingen “shows signs of efficacy” det høres ikke oppløftende ut